JP2005536553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005536553A5 JP2005536553A5 JP2004531141A JP2004531141A JP2005536553A5 JP 2005536553 A5 JP2005536553 A5 JP 2005536553A5 JP 2004531141 A JP2004531141 A JP 2004531141A JP 2004531141 A JP2004531141 A JP 2004531141A JP 2005536553 A5 JP2005536553 A5 JP 2005536553A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- benzyl
- tolyl
- compound according
- propyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 34
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 23
- -1 chloro, fluoro, methyl Chemical group 0.000 claims 16
- 125000003710 aryl alkyl group Chemical group 0.000 claims 15
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 125000003107 substituted aryl group Chemical group 0.000 claims 12
- 125000000547 substituted alkyl group Chemical group 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 230000002062 proliferating effect Effects 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 6
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 4
- FKPLHKXAYQVKJX-UHFFFAOYSA-N 3-benzyl-2-[1-[2-(4-methylphenyl)piperazin-1-yl]propyl]quinazolin-4-one Chemical compound N=1C2=CC=CC=C2C(=O)N(CC=2C=CC=CC=2)C=1C(CC)N1CCNCC1C1=CC=C(C)C=C1 FKPLHKXAYQVKJX-UHFFFAOYSA-N 0.000 claims 3
- WJYYIKKYYOGNFG-UHFFFAOYSA-N 3-benzyl-7-chloro-2-[1-[2-(4-methylphenyl)piperazin-1-yl]propyl]quinazolin-4-one Chemical compound N=1C2=CC(Cl)=CC=C2C(=O)N(CC=2C=CC=CC=2)C=1C(CC)N1CCNCC1C1=CC=C(C)C=C1 WJYYIKKYYOGNFG-UHFFFAOYSA-N 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- KYIDPRGJDYRFLP-UHFFFAOYSA-N 3-benzyl-2-[2-methyl-1-[2-(4-methylphenyl)piperazin-1-yl]propyl]quinazolin-4-one Chemical compound N=1C2=CC=CC=C2C(=O)N(CC=2C=CC=CC=2)C=1C(C(C)C)N1CCNCC1C1=CC=C(C)C=C1 KYIDPRGJDYRFLP-UHFFFAOYSA-N 0.000 claims 2
- JEDRXLSPWBGDQE-UHFFFAOYSA-N 3-benzyl-7-chloro-2-[2-methyl-1-[2-(4-methylphenyl)piperazin-1-yl]propyl]quinazolin-4-one Chemical compound N=1C2=CC(Cl)=CC=C2C(=O)N(CC=2C=CC=CC=2)C=1C(C(C)C)N1CCNCC1C1=CC=C(C)C=C1 JEDRXLSPWBGDQE-UHFFFAOYSA-N 0.000 claims 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 208000006029 Cardiomegaly Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 102000010638 Kinesin Human genes 0.000 claims 2
- 108010063296 Kinesin Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims 2
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000005059 halophenyl group Chemical group 0.000 claims 2
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 206010020718 hyperplasia Diseases 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- SGDOOIVSJXSDJC-UHFFFAOYSA-N 3-benzyl-2-[1-(7-phenyl-1,4-diazepan-1-yl)propyl]quinazolin-4-one Chemical compound N=1C2=CC=CC=C2C(=O)N(CC=2C=CC=CC=2)C=1C(CC)N1CCNCCC1C1=CC=CC=C1 SGDOOIVSJXSDJC-UHFFFAOYSA-N 0.000 claims 1
- OIZVKDWNVBWRPL-UHFFFAOYSA-N 3-benzyl-2-[2-methyl-1-(7-phenyl-1,4-diazepan-1-yl)propyl]quinazolin-4-one Chemical compound N=1C2=CC=CC=C2C(=O)N(CC=2C=CC=CC=2)C=1C(C(C)C)N1CCNCCC1C1=CC=CC=C1 OIZVKDWNVBWRPL-UHFFFAOYSA-N 0.000 claims 1
- VHVQLZYPUJWRTF-UHFFFAOYSA-N 3-benzyl-7-chloro-2-[1-(7-phenyl-1,4-diazepan-1-yl)propyl]quinazolin-4-one Chemical compound N=1C2=CC(Cl)=CC=C2C(=O)N(CC=2C=CC=CC=2)C=1C(CC)N1CCNCCC1C1=CC=CC=C1 VHVQLZYPUJWRTF-UHFFFAOYSA-N 0.000 claims 1
- CWJYEZBCYQJXQT-UHFFFAOYSA-N 3-benzyl-7-chloro-2-[2-methyl-1-(7-phenyl-1,4-diazepan-1-yl)propyl]quinazolin-4-one Chemical compound N=1C2=CC(Cl)=CC=C2C(=O)N(CC=2C=CC=CC=2)C=1C(C(C)C)N1CCNCCC1C1=CC=CC=C1 CWJYEZBCYQJXQT-UHFFFAOYSA-N 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40486402P | 2002-08-21 | 2002-08-21 | |
| PCT/US2003/026093 WO2004018058A2 (en) | 2002-08-21 | 2003-08-20 | Compounds, compositions, and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005536553A JP2005536553A (ja) | 2005-12-02 |
| JP2005536553A5 true JP2005536553A5 (enExample) | 2006-08-03 |
Family
ID=31946773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004531141A Pending JP2005536553A (ja) | 2002-08-21 | 2003-08-20 | 化合物、組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20040048853A1 (enExample) |
| EP (1) | EP1539180A4 (enExample) |
| JP (1) | JP2005536553A (enExample) |
| AU (1) | AU2003262747A1 (enExample) |
| WO (1) | WO2004018058A2 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US7230000B1 (en) | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
| WO2003070701A2 (en) * | 2002-02-15 | 2003-08-28 | Cytokinetics, Inc. | Syntheses of quinazolinones |
| WO2003097053A1 (en) * | 2002-05-09 | 2003-11-27 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| KR20050036911A (ko) | 2002-05-09 | 2005-04-20 | 싸이토키네틱스, 인코포레이티드 | 화합물들, 방법 및 조성물 |
| WO2003103575A2 (en) | 2002-05-23 | 2003-12-18 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| JP2005538062A (ja) | 2002-06-14 | 2005-12-15 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、および方法 |
| AU2003256805A1 (en) * | 2002-07-23 | 2004-02-09 | Cytokinetics, Inc. | Compounds compositions and methods |
| AU2003262747A1 (en) * | 2002-08-21 | 2004-03-11 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| AU2003277079A1 (en) | 2002-09-30 | 2004-05-04 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| US20070149500A1 (en) * | 2003-01-17 | 2007-06-28 | Han-Jie Zhou | Compounds, compositions, and methods |
| KR20050122220A (ko) * | 2003-03-25 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 디펩티딜 펩티다제 억제제 |
| JP2007510660A (ja) * | 2003-11-07 | 2007-04-26 | サイトキネティクス・インコーポレーテッド | 化合物、組成物及び方法 |
| US7939539B2 (en) | 2003-11-25 | 2011-05-10 | Novartis Vaccines And Diagnostics, Inc. | Quinazolinone compounds as anticancer agents |
| EP1692112A4 (en) | 2003-12-08 | 2008-09-24 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS, AND METHODS |
| CA2563038C (en) * | 2004-04-02 | 2013-10-29 | Gaik Beng Kok | Neurologically-active compounds |
| DK1753723T3 (da) | 2004-05-21 | 2008-10-20 | Novartis Vaccines & Diagnostic | Substituerede quinolinderivater som mitotiske kinesininhibitorer |
| JP4836280B2 (ja) | 2004-06-18 | 2011-12-14 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 癌を治療するためのキネシンスピンドルタンパク質（ｋｓｐ）阻害剤としてのｎ−（１−（１−ベンジル−４−フェニル−１ｈ−イミダゾール−２−イル）−２，２−ジメチルプロピル）ベンズアミド誘導体および関連化合物 |
| MY141233A (en) | 2004-08-18 | 2010-03-31 | Astrazeneca Ab | Enantiomers of selected fused heterocyclics and uses thereof |
| MX2007004699A (es) | 2004-10-19 | 2007-06-14 | Novartis Vaccines & Diagnostic | Derivados de indol y bencimidazol. |
| JP2008520744A (ja) | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 抗炎症性ピラゾロピリミジン |
| US20100093767A1 (en) * | 2004-12-03 | 2010-04-15 | Takeda San Diego, Inc. | Mitotic Kinase Inhibitors |
| NZ560320A (en) | 2005-01-25 | 2011-02-25 | Prolexys Pharmaceuticals Inc | Quinoxaline derivatives as antitumor agents |
| EP2010505B1 (en) * | 2006-03-28 | 2012-12-05 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| AU2007347115A1 (en) | 2006-04-04 | 2008-10-23 | The Regents Of The University Of California | PI3 kinase antagonists |
| WO2008013987A2 (en) * | 2006-07-27 | 2008-01-31 | Prolexys Pharmaceuticals, Inc. | N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones |
| MX2009003673A (es) * | 2006-10-04 | 2009-04-22 | Pfizer Prod Inc | Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio. |
| EP2091926B1 (en) | 2006-11-13 | 2015-10-21 | Novartis AG | Substituted pyrazole and triazole compounds as ksp inhibitors |
| CA2669399A1 (en) * | 2006-11-13 | 2008-05-29 | Eli Lilly & Co. | Thienopyrimidinones for treatment of inflammatory disorders and cancers |
| AU2008205169B2 (en) | 2007-01-05 | 2012-02-02 | Novartis Ag | Imidazole derivatives as kinesin spindle protein inhibitors (Eg-5) |
| EP2896624B1 (en) * | 2007-03-28 | 2016-07-13 | Atir Holding S.A. | Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof |
| US20110123486A1 (en) * | 2007-06-25 | 2011-05-26 | Prolexys Pharmaceuticals, Inc. | Methods of treating multiple myeloma and resistant cancers |
| GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
| DK2240451T3 (da) | 2008-01-04 | 2017-11-20 | Intellikine Llc | Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| BRPI0915231A2 (pt) | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| CA2740885C (en) | 2008-10-16 | 2018-04-03 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
| US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| EP2427195B1 (en) | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
| AU2011255218B2 (en) | 2010-05-21 | 2015-03-12 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| AU2011326427B2 (en) | 2010-11-10 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| PE20180318A1 (es) | 2011-01-10 | 2018-02-09 | Infinity Pharmaceuticals Inc | Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas |
| JP6130305B2 (ja) | 2011-02-23 | 2017-05-17 | インテリカイン， エルエルシー | キナーゼ阻害剤の組み合わせおよびそれらの使用 |
| WO2012140642A1 (en) | 2011-04-10 | 2012-10-18 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| WO2013012915A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| WO2013012918A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| AR091790A1 (es) | 2011-08-29 | 2015-03-04 | Infinity Pharmaceuticals Inc | Derivados de isoquinolin-1-ona y sus usos |
| JP6342805B2 (ja) | 2011-09-02 | 2018-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途 |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| IN2015MN00002A (enExample) | 2012-07-09 | 2015-10-16 | Lupin Ltd | |
| KR20150061651A (ko) | 2012-09-26 | 2015-06-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ire1의 조절 |
| LT2914296T (lt) | 2012-11-01 | 2018-09-25 | Infinity Pharmaceuticals, Inc. | Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2015051244A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3119397B1 (en) | 2014-03-19 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US10088464B2 (en) * | 2015-06-16 | 2018-10-02 | Lunatech, Llc | Systems and methods for analyzing pharmaceuticals |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| UA125216C2 (uk) | 2016-06-24 | 2022-02-02 | Інфініті Фармасьютікалз, Інк. | Комбінована терапія |
| TWI824050B (zh) * | 2018-10-31 | 2023-12-01 | 西班牙塔拉森斯調理協會 | 化合物、製備化合物的方法、化合物的用途、藥物組合物、用作藥物的化合物及用作治療疼痛的藥物的化合物 |
| CA3153302A1 (en) * | 2019-10-10 | 2021-04-15 | Carmen ALMANSA-ROSALES | Homopiperazinyl and homopiperidinyl quinazolin-4(3h)-one derivatives having multimodal activity against pain |
| CN117024357A (zh) * | 2023-07-03 | 2023-11-10 | 潍坊医学院 | 一种针对brca突变的选择性抑制剂及其用途 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1053063A (enExample) * | 1963-05-18 | |||
| US3320124A (en) * | 1964-07-20 | 1967-05-16 | American Cyanamid Co | Method for treating coccidiosis with quinazolinones |
| US3846549A (en) * | 1966-09-03 | 1974-11-05 | Boehringer Sohn Ingelheim | Pharmaceutical compositions containing an n-(1-bicyclic aryl-propyl -2)-n-phenyl-piperazine |
| US3723432A (en) * | 1968-11-12 | 1973-03-27 | Sandoz Ag | 1-substituted-4-aryl-2(1h)-quinazolinones and their preparation |
| DE2027645A1 (de) * | 1970-06-05 | 1971-12-09 | Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz | Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel |
| US3962244A (en) * | 1971-01-23 | 1976-06-08 | Hoechst Aktiengesellschaft | Benzene sulfonyl ureas |
| US3740442A (en) * | 1972-01-14 | 1973-06-19 | Sandoz Ag | 2-isopropylaminobenzophenones in treating inflammation |
| US4011324A (en) * | 1976-01-20 | 1977-03-08 | Pfizer Inc. | Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents |
| GB1577730A (en) * | 1976-10-23 | 1980-10-29 | Beecham Group Ltd | Treatment of infections with pseudomonicacid salts or esters thereof |
| US4281127A (en) * | 1979-07-09 | 1981-07-28 | Hoffmann-La Roche Inc. | Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives |
| DE3177130D1 (de) * | 1980-08-30 | 1990-01-11 | Hoechst Ag | Aminosaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung. |
| GB8524663D0 (en) * | 1985-10-07 | 1985-11-13 | Fujisawa Pharmaceutical Co | Quinazoline derivatives |
| DE3609598A1 (de) * | 1986-03-21 | 1987-10-01 | Hoechst Ag | 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung |
| GB8607683D0 (en) * | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
| US5187167A (en) * | 1986-03-27 | 1993-02-16 | Imperial Chemical Industries Plc | Pharmaceutical compositions comprising quinazolin-4-one derivatives |
| US4670560A (en) * | 1986-04-28 | 1987-06-02 | Ortho Pharmaceutical Corporation | Thienopyrimidine-2,4-dione derivatives and intermediates thereof |
| US4729996A (en) * | 1986-05-29 | 1988-03-08 | Harbor Branch Oceanographic Institution, Inc. | Antitumor compositions and their methods of use |
| GB8707053D0 (en) * | 1987-03-25 | 1987-04-29 | Ici Plc | Anti-tumour agents |
| US4866084A (en) * | 1987-07-17 | 1989-09-12 | Harbor Branch Oceanographic Institution, Inc. | Topsentin compounds effective against viruses and certain tumors |
| US4808590A (en) * | 1987-07-17 | 1989-02-28 | Harbor Branch Oceanographic Institution, Inc. | Antiviral, antitumor and antifungal compositions and their methods of use |
| US5756450A (en) * | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
| US4857530A (en) * | 1987-11-03 | 1989-08-15 | Warner-Lambert Company | Substituted quinazolinones as anticancer agents |
| GB8827820D0 (en) * | 1988-11-29 | 1988-12-29 | Janssen Pharmaceutica Nv | (1h-azol-1-ylmethyl)substituted quinoline derivatives |
| GB8827988D0 (en) * | 1988-11-30 | 1989-01-05 | Smith Kline French Lab | Chemical compounds |
| AU640016B2 (en) * | 1990-05-30 | 1993-08-12 | Imperial Chemical Industries Plc | Hydroquinazoline derivatives |
| FR2665159B1 (fr) * | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| EP0481614A1 (en) * | 1990-10-01 | 1992-04-22 | Merck & Co. Inc. | Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists |
| GB9105771D0 (en) * | 1991-03-19 | 1991-05-01 | Cancer Res Inst Royal | Anti-cancer compounds |
| US5714493A (en) * | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| US5316906A (en) * | 1991-08-23 | 1994-05-31 | Molecular Probes, Inc. | Enzymatic analysis using substrates that yield fluorescent precipitates |
| US5204354A (en) * | 1992-02-14 | 1993-04-20 | Merck & Co., Inc. | Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders |
| US5430148A (en) * | 1992-03-31 | 1995-07-04 | Agouron Pharmaceuticals, Inc. | Antiproliferative quinazolines |
| US5780476A (en) * | 1992-11-16 | 1998-07-14 | Cell Therapeutics, Inc. | Hydroxyl-containing xanthine compounds |
| AU6087894A (en) * | 1993-01-14 | 1994-08-15 | Cell Therapeutics, Inc. | Acetal or ketal substituted therapeutic compounds |
| WO1994016704A1 (en) * | 1993-01-19 | 1994-08-04 | Cell Therapeutics, Inc. | Oxime-substituted therapeutic compounds |
| US5837703A (en) * | 1993-03-31 | 1998-11-17 | Cell Therapeutics, Inc. | Amino-alcohol substituted cyclic compounds |
| US5342944A (en) * | 1993-07-19 | 1994-08-30 | American Cyanamid Company | Process for the preparation of 2-alkyl-3,5,6,7- or 8-substituted-4(3H)-quinazolinones |
| CA2113229C (en) * | 1994-01-11 | 1999-04-20 | Mark Pines | Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof |
| AU1831395A (en) * | 1994-01-14 | 1995-08-01 | Cell Therapeutics, Inc. | Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf |
| CA2183562A1 (en) * | 1994-02-18 | 1995-08-24 | J. Peter Klein | Intracellular signalling mediators |
| AU2096895A (en) * | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| GB9404485D0 (en) * | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| US5801182A (en) * | 1994-03-24 | 1998-09-01 | Cell Therapeutics, Inc. | Amine substituted compounds |
| US5807861A (en) * | 1994-03-24 | 1998-09-15 | Cell Therapeutics, Inc. | Amine substituted xanthinyl compounds |
| US5756502A (en) * | 1994-08-08 | 1998-05-26 | Warner-Lambert Company | Quinazolinone derivatives as cholyecystokinin (CCK) ligands |
| JPH09165385A (ja) * | 1994-08-26 | 1997-06-24 | Kyowa Hakko Kogyo Co Ltd | キナゾリン誘導体 |
| US5891879A (en) * | 1994-08-31 | 1999-04-06 | Hadasit Medical Research Services & Development Co., Inc. | Quinazolinone-containing pharmaceutical compositions and methods for the use thereof |
| US5753664A (en) * | 1995-03-16 | 1998-05-19 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds, their production and use |
| US6245768B1 (en) * | 1995-06-05 | 2001-06-12 | Neurogen Corporation | 1-(N′-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| WO1997008153A1 (en) * | 1995-08-30 | 1997-03-06 | Otsuka Pharmaceutical Factory, Inc. | Process for producing quinazolin-4-one derivatives |
| US5783577A (en) * | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
| DE19546918A1 (de) * | 1995-12-15 | 1997-06-19 | Bayer Ag | Bicyclische Heterocyclen |
| DE19615262A1 (de) * | 1996-04-18 | 1997-10-23 | Bayer Ag | Heteroverknüpfte Phenylglycinolamide |
| US5948775A (en) * | 1997-03-19 | 1999-09-07 | American Home Products Corporation | 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones |
| US5939421A (en) * | 1997-07-01 | 1999-08-17 | Signal Pharmaceuticals, Inc. | Quinazoline analogs and related compounds and methods for treating inflammatory conditions |
| US6207403B1 (en) * | 1998-01-08 | 2001-03-27 | The Regents Of The University Of California | Kinesin motor modulators derived from the marine sponge Adocia |
| US6214879B1 (en) * | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
| US6559160B1 (en) * | 1999-08-27 | 2003-05-06 | Chemocentryx, Inc. | Compounds and methods for modulating cxcr3 function |
| DE60017157T2 (de) * | 1999-09-16 | 2005-12-22 | Curis, Inc., Cambridge | Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen |
| US6545004B1 (en) * | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US6380205B1 (en) * | 1999-10-29 | 2002-04-30 | Merck & Co., Inc. | 2-cyclohexyl quinazoline NMDA/NR2B antagonists |
| US6476041B1 (en) * | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| US7115653B2 (en) * | 2000-03-30 | 2006-10-03 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| EP1278748B1 (en) * | 2000-04-25 | 2011-03-23 | ICOS Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| IL137363A (en) * | 2000-07-18 | 2005-12-18 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing mupirocin |
| KR100883184B1 (ko) * | 2000-12-11 | 2009-02-12 | 암젠 인코포레이션 | Ｃｘｃｒ3 길항제 |
| AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| US20020088819A1 (en) * | 2001-01-11 | 2002-07-11 | Paokai Electronic Enterprise Co. Ltd. | Article-retrieving machine |
| JP2004529918A (ja) * | 2001-04-09 | 2004-09-30 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | インテグリンに由来する疾患の治療のためのキナゾリンおよびキナゾリン類似化合物 |
| US7365199B2 (en) * | 2001-04-20 | 2008-04-29 | Fujifilm Corporation | Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound |
| US20030096813A1 (en) * | 2001-04-20 | 2003-05-22 | Jingrong Cao | Compositions useful as inhibitors of GSK-3 |
| US6596723B1 (en) * | 2001-07-16 | 2003-07-22 | Essential Therapeutics, Inc. | Fungal efflux pump inhibitors |
| US20030144350A1 (en) * | 2001-07-20 | 2003-07-31 | Adipogenix, Inc. | Fat accumulation-modulation compounds |
| WO2003020280A2 (en) * | 2001-09-05 | 2003-03-13 | Minerva Biotechnologies Corporation | Compositions and use thereof in the treatment of cancer |
| JP2005507876A (ja) * | 2001-09-05 | 2005-03-24 | ミナーバ バイオテクノロジーズ コーポレイション | 癌を治療する組成物および方法 |
| WO2003039460A2 (en) * | 2001-11-07 | 2003-05-15 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| US7053216B2 (en) * | 2001-11-19 | 2006-05-30 | Iconix Pharmaceuticals, Inc. | Modulators of Rho C activity |
| WO2003043995A1 (en) * | 2001-11-20 | 2003-05-30 | Cytokinetics, Inc. | Process for the racemization of chiral quinazolinones |
| WO2003049527A2 (en) * | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| JP4467979B2 (ja) * | 2001-12-06 | 2010-05-26 | メルク・シャープ・エンド・ドーム・コーポレイション | 有糸分裂キネシン阻害剤 |
| DE60222302T2 (de) * | 2001-12-06 | 2008-05-29 | Merck & Co., Inc. | Inhibitoren von mitotischem kinesin |
| WO2003070701A2 (en) * | 2002-02-15 | 2003-08-28 | Cytokinetics, Inc. | Syntheses of quinazolinones |
| US7074805B2 (en) * | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| US20030158188A1 (en) * | 2002-02-20 | 2003-08-21 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| KR20050036911A (ko) * | 2002-05-09 | 2005-04-20 | 싸이토키네틱스, 인코포레이티드 | 화합물들, 방법 및 조성물 |
| WO2003097053A1 (en) * | 2002-05-09 | 2003-11-27 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| WO2003103575A2 (en) * | 2002-05-23 | 2003-12-18 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| JP2005538062A (ja) * | 2002-06-14 | 2005-12-15 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、および方法 |
| US20040092561A1 (en) * | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
| AU2003256805A1 (en) * | 2002-07-23 | 2004-02-09 | Cytokinetics, Inc. | Compounds compositions and methods |
| IL150907A (en) * | 2002-07-25 | 2007-07-04 | Stephan Cherkez | Process for the preparation of stable amorphous calcium pseudomonate |
| AU2003262747A1 (en) * | 2002-08-21 | 2004-03-11 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| US7022850B2 (en) * | 2003-05-22 | 2006-04-04 | Bristol-Myers Squibb Co. | Bicyclicpyrimidones and their use to treat diseases |
| WO2005005397A1 (en) * | 2003-07-02 | 2005-01-20 | F. Hoffmann-La Roche Ag | 5-substituted quinazolinone derivatives |
| CA2536633A1 (en) * | 2003-09-10 | 2005-03-24 | Icagen, Inc. | Fused ring heterocycles as potassium channel modulators |
| US20050152940A1 (en) * | 2003-12-23 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
-
2003
- 2003-08-20 AU AU2003262747A patent/AU2003262747A1/en not_active Abandoned
- 2003-08-20 US US10/644,244 patent/US20040048853A1/en not_active Abandoned
- 2003-08-20 WO PCT/US2003/026093 patent/WO2004018058A2/en not_active Ceased
- 2003-08-20 EP EP03793179A patent/EP1539180A4/en not_active Withdrawn
- 2003-08-20 JP JP2004531141A patent/JP2005536553A/ja active Pending
-
2006
- 2006-03-06 US US11/370,263 patent/US20060264420A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005536553A5 (enExample) | ||
| JP2006501201A5 (enExample) | ||
| EA029085B1 (ru) | Способ лечения иммуноопосредуемых и воспалительных заболеваний с помощью 3-[4-(4-морфолин-4-илметилбензилокси)-1-оксо-1,3-дигидроизоиндол-2-ил]пиперидин-2,6-диона | |
| RU2003116059A (ru) | Арилэфирзамещенные имидазохинолины | |
| CZ228295A3 (en) | The use of carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation | |
| JP2005538062A5 (enExample) | ||
| KR930002330A (ko) | 아미노-치환된 피페라진 유도체 | |
| JP2005536475A5 (enExample) | ||
| RU2005132222A (ru) | Применение производных (3-тригалометилфенокси)-(4-галофенил)уксусной кислоты для лечения гиперурикемии и фармацевтическая композиция, их содержащая | |
| JP2006513202A5 (enExample) | ||
| JP2005533835A5 (enExample) | ||
| CA2170644A1 (en) | Multiple unit pharmaceutical preparation containing proton pump inhibitor | |
| JP2009538327A5 (enExample) | ||
| JP2002505286A5 (enExample) | ||
| TW201919612A (zh) | 包含帕博西尼（ｐａｌｂｏｃｉｃｌｉｂ）及６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧基苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－甲酸的組合 | |
| JP2003519228A5 (enExample) | ||
| JP2008502721A5 (enExample) | ||
| JP2008510758A5 (enExample) | ||
| JP2006510606A5 (enExample) | ||
| CA2302568A1 (en) | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents | |
| JP2005519885A5 (enExample) | ||
| RU2006139644A (ru) | Новые растворимые в воде пролекарства | |
| CN110573148A (zh) | 特发性肺纤维化的治疗 | |
| JP2021503448A5 (enExample) | ||
| JP2005501091A5 (enExample) |